Home Ingredients genVida® (non-soy genistein)
Women's HealthMenopause SupportBone Health

genVida® (non-soy genistein)

Genistein (chemically and biotechnologically produced)
Evidence Level
Moderate
2 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

genVida® is a branded non-soy form of pure genistein produced by DSM that delivers the same isoflavone phytoestrogen studied in landmark trials of soy-derived genistein, without the soy protein matrix. It is positioned for menopause, bone, and women's health formulations where a soy-free, allergen-friendly source of standardized genistein aglycone is desired. The branded ingredient leans on the broader genistein literature, including 12- to 24-month randomized trials in osteopenic postmenopausal women using approximately 54 mg per day that demonstrated improvements in bone mineral density, hot flash frequency, quality of life, and select cardiovascular risk markers. genVida is best understood as a delivery and sourcing innovation around the same molecule.

Studied Dose 54 mg/day genistein aglycone (typical genVida delivery).
Active Compound Pharmaceutical-grade genistein aglycone (non-soy branded form).

Benefits

Supports bone health in postmenopausal women

As a source of pure genistein aglycone, genVida draws on randomized controlled trial evidence showing 54 mg per day for 24 months can support bone mineral density and bone turnover markers in osteopenic postmenopausal women.

Supported by Trial 1, Trial 2

Helps reduce menopausal hot flashes

Daily genistein supplementation has been associated in placebo-controlled trials with progressive reductions in hot flash frequency over 3 to 12 months, supporting comfort during the menopausal transition.

Supported by Trial 2

Provides a soy-free isoflavone source

As a non-soy genistein ingredient, genVida supplies standardized phytoestrogen activity for consumers and formulators who prefer to avoid soy due to allergies, sensitivities, or formulation preferences.

Supported by Trial 1, Trial 2

Supports menopausal quality of life

Long-term genistein trials in postmenopausal women have shown improvements in quality-of-life and self-reported mood measures alongside skeletal endpoints, supporting overall well-being during the menopausal transition.

Supported by Trial 2, Trial 1

Mechanism of action

1

Selective ER-beta agonism

Like soy-derived genistein, genVida-delivered genistein preferentially activates estrogen receptor beta over ER-alpha, producing tissue-selective phytoestrogen effects in bone, vasculature, and central thermoregulatory pathways.

2

Modulation of bone remodeling

Genistein supports osteoblast differentiation and reduces osteoclast-mediated bone resorption through ER-beta-mediated signaling, contributing to gains in bone mineral density observed in long-term trials.

3

Antioxidant and signaling modulation

Genistein scavenges reactive oxygen species, inhibits select tyrosine kinases, and modulates inflammatory pathways relevant to cardiovascular and metabolic health alongside its phytoestrogenic activity.

Clinical trials

1
24-month bone density RCT (parent compound)

Multicenter RCT of 54 mg/day genistein aglycone vs placebo for 24 months with calcium and vitamin D in both arms.

389 osteopenic postmenopausal women.

Genistein recipients showed BMD increases at the lumbar spine and femoral neck while placebo recipients showed decreases, with favorable changes in bone turnover markers. Findings are directly applicable to the same dose of genistein delivered via genVida.

2
12-month hot flush RCT (parent compound)

Randomized, double-blind, EPT- and placebo-controlled study; 54 mg/day genistein for 12 months.

90 early postmenopausal women aged 47–57.

Daily flushes reduced significantly versus placebo by 22% at 3 months, 29% at 6 months, and 24% at 12 months in the genistein group, providing direct support for use of pure genistein—the active in genVida—for menopausal vasomotor symptoms.

Side effects and drug interactions

Common Potential side effects

Mild gastrointestinal complaints such as bloating, gas, or constipation can occur.
Breast tenderness has been reported infrequently with phytoestrogen use.
Headache or transient discomfort may occur in sensitive individuals.
Theoretical caution remains about high-dose use in hormone-sensitive cancers.

Important Drug interactions

May interact with tamoxifen and aromatase inhibitors via estrogen receptor activity.
Theoretical interaction with thyroid hormone replacement; separate dosing recommended.
May affect anticoagulant response; INR monitoring is reasonable with warfarin.
Could compound effects of hormone replacement therapy or oral contraceptives.

More Women's Health Ingredients

Women's Health
Chasteberry / Vitex (Vitex agnus-castus)
Chasteberry (Vitex agnus-castus) fruit extract is the most clinically studied herbal medic…
Women's Health
Libifem® (Fenugreek for Female Libido)
Libifem® is the SAME standardized fenugreek seed extract as Testofen® (Fenuside™ furostano…
Women's Health
Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®)
Lactobacillus fermentum CECT5716 (commercialized as Lc40 and Hereditum®) is a probiotic st…
Women's Health
ERr 731® (Rheum rhaponticum extract)
ERr 731® is a standardized extract of Siberian rhubarb (Rheum rhaponticum) root produced b…

Frequently asked questions about genVida® (non-soy genistein)

What is genVida?

genVida® is a branded non-soy form of pure genistein produced by DSM that delivers the same isoflavone phytoestrogen studied in landmark trials of soy-derived genistein, without the soy protein matrix.

What is genVida used for?

genVida is researched primarily for Women's Health, Menopause Support, and Bone Health. As a source of pure genistein aglycone, genVida draws on randomized controlled trial evidence showing 54 mg per day for 24 months can support bone mineral density and bone turnover markers in osteopenic postmenopausal women.

What is the recommended dosage of genVida?

The clinically studied dose is 54 mg/day genistein aglycone (typical genVida delivery). Always follow the product label and check with a healthcare provider for personal advice.

Is genVida safe, and does it have side effects?

For most healthy adults, genVida is well tolerated at studied doses. Reported effects can include: Mild gastrointestinal complaints such as bloating, gas, or constipation can occur. Breast tenderness has been reported infrequently with phytoestrogen use. It may also interact with some medications. genVida is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does genVida interact with any medications?

Possible interactions include: May interact with tamoxifen and aromatase inhibitors via estrogen receptor activity. Theoretical interaction with thyroid hormone replacement; separate dosing recommended. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for genVida?

NutraSmarts rates the evidence for genVida as Moderate (3 out of 5). It is backed by 2 clinical trials and 2 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(2 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Annals of Internal Medicine. 2007;Ann Intern Med. 2007 Jun 19;146(12):839-47..PubMedUsed to support: Pivotal 24-month bone density RCT for the genistein molecule delivered by genVida.
  2. Crisafulli A, Marini H, Bitto A, Altavilla D, Squadrito G, Romeo A, et al. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause. 2004;Menopause. 2004 Jul-Aug;11(4):400-4..PubMedUsed to support: 12-month hot flush RCT for the same genistein active delivered by genVida.